226 related articles for article (PubMed ID: 8119308)
1. Cromakalim does not protect against skeletal muscle fatigue in an anaesthetized rat model of acute hindlimb ischaemia.
Trezise DJ; Drew GM; Roach AG; Watts IS; Weston AH
Eur J Pharmacol; 1993 Nov; 250(1):109-16. PubMed ID: 8119308
[TBL] [Abstract][Full Text] [Related]
2. Effect of cromakalim on skeletal muscle function and blood flow in the ferret ischemic hindlimb.
Weselcouch EO; Baird AJ
Pharmacology; 1994 Aug; 49(2):75-85. PubMed ID: 7972324
[TBL] [Abstract][Full Text] [Related]
3. KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats.
Baczkó I; Leprán I; Papp JG
Eur J Pharmacol; 1997 Apr; 324(1):77-83. PubMed ID: 9137916
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the airways relaxant and hypotensive potencies of the potassium channel activators BRL 55834 and levcromakalim (BRL 38227) in vivo in guinea-pigs and rats.
Bowring NE; Arch JR; Buckle DR; Taylor JF
Br J Pharmacol; 1993 Aug; 109(4):1133-9. PubMed ID: 8401925
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers.
Lawson K; Barras M; Zazzi-Sudriez E; Martin DJ; Armstrong JM; Hicks PE
Br J Pharmacol; 1992 Sep; 107(1):58-65. PubMed ID: 1422579
[TBL] [Abstract][Full Text] [Related]
6. The individual enantiomers of cis-cromakalim possess K+ channel opening activity.
Quast U; Villhauer EB
Eur J Pharmacol; 1993 Apr; 245(2):165-71. PubMed ID: 8491256
[TBL] [Abstract][Full Text] [Related]
7. Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia.
D'Alonzo AJ; Darbenzio RB; Hess TA; Sewter JC; Sleph PG; Grover GJ
Cardiovasc Res; 1994 Jun; 28(6):881-7. PubMed ID: 7923295
[TBL] [Abstract][Full Text] [Related]
8. ATP-sensitive potassium channels and skeletal muscle function in vitro.
Weselcouch EO; Sargent C; Wilde MW; Smith MA
J Pharmacol Exp Ther; 1993 Oct; 267(1):410-6. PubMed ID: 8229769
[TBL] [Abstract][Full Text] [Related]
9. Analysis of pulmonary and systemic vascular responses to cromakalim, an activator of K+ATP channels.
Minkes RK; Kvamme P; Higuera TR; Nossaman BD; Kadowitz PJ
Am J Physiol; 1991 Mar; 260(3 Pt 2):H957-66. PubMed ID: 1825747
[TBL] [Abstract][Full Text] [Related]
10. Effects of cromakalim, a potassium channel opener, on regional blood flow in conscious spontaneously hypertensive rats.
Shoji T; Aki Y; Fukui K; Tamaki T; Iwao H; Abe Y
Eur J Pharmacol; 1990 Sep; 186(1):119-23. PubMed ID: 2282933
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N
Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827
[TBL] [Abstract][Full Text] [Related]
12. Combined administration of an IK(ATP) activator and Ito blocker increases coronary flow independently of effects on heart rate, QT interval, and ischaemia-induced ventricular fibrillation in rats.
Rees SA; Tsuchihashi K; Hearse DJ; Curtis MJ
J Cardiovasc Pharmacol; 1993 Sep; 22(3):343-9. PubMed ID: 7504122
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of K+ conductance improves in vitro the contraction force of skeletal muscle in hypokalemic periodic paralysis.
Grafe P; Quasthoff S; Strupp M; Lehmann-Horn F
Muscle Nerve; 1990 May; 13(5):451-7. PubMed ID: 2345562
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts.
D'Alonzo AJ; Grover GJ; Darbenzio RB; Sewter JC; Hess TA; Dzwonczyk S; Sleph PG
Pharmacology; 1996 Feb; 52(2):101-12. PubMed ID: 8851631
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of muscle blood cell flux and pO2 by cromakalim (BRL 34915) and other compounds enhancing membrane K+ conductance, but not by Ca2+ antagonists or hydralazine, in an animal model of occlusive arterial disease.
Angerbach D; Nicholson CD
Naunyn Schmiedebergs Arch Pharmacol; 1988 Mar; 337(3):341-6. PubMed ID: 3393236
[TBL] [Abstract][Full Text] [Related]
16. Effects of rubidium on responses to potassium channel openers in rat isolated aorta.
Greenwood IA; Weston AH
Br J Pharmacol; 1993 Aug; 109(4):925-32. PubMed ID: 8401946
[TBL] [Abstract][Full Text] [Related]
17. Effects of cromakalim (BRL 34915) and pinacidil on normal and hypertrophied rat detrusor in vitro.
Malmgren A; Andersson KE; Andersson PO; Fovaeus M; Sjögren C
J Urol; 1990 Apr; 143(4):828-34. PubMed ID: 2313820
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of YM099, a novel K+ channel opener, in anesthetized and conscious dogs.
Uchida W; Hirano Y; Taguchi T; Masuda N; Shirai Y; Satoh N; Takenaka T
Eur J Pharmacol; 1994 Nov; 264(3):285-93. PubMed ID: 7698167
[TBL] [Abstract][Full Text] [Related]
19. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration.
Grover GJ; D'Alonzo AJ; Parham CS; Darbenzio RB
J Cardiovasc Pharmacol; 1995 Jul; 26(1):145-52. PubMed ID: 7564356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
